Latest Insider Transactions at Natera, Inc. (NTRA)
This section provides a real-time view of insider transactions for Natera, Inc. (NTRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Natera, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Natera, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 17
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,500
-1.31%
|
$267,000
$178.97 P/Share
|
|
Oct 15
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
3,070
-0.32%
|
$537,250
$175.16 P/Share
|
|
Oct 01
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
14,083
-2.14%
|
$2,253,280
$160.15 P/Share
|
|
Oct 01
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
3,000
-0.84%
|
$477,000
$159.86 P/Share
|
|
Sep 30
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,491
-3.48%
|
$403,542
$162.05 P/Share
|
|
Sep 30
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
9,109
-5.14%
|
$1,475,658
$162.05 P/Share
|
|
Sep 30
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,364
-0.67%
|
$220,968
$162.05 P/Share
|
|
Sep 29
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+8.02%
|
-
|
|
Sep 29
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+9.57%
|
-
|
|
Sep 29
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+1.21%
|
-
|
|
Sep 19
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
11,000
-5.6%
|
$1,969,000
$179.91 P/Share
|
|
Sep 19
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
25,527
-0.54%
|
$4,594,860
$180.91 P/Share
|
|
Sep 18
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
14,473
-0.61%
|
$2,605,140
$180.13 P/Share
|
|
Sep 18
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
10,000
-40.0%
|
$1,800,000
$180.0 P/Share
|
|
Sep 17
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
3,070
-0.63%
|
$540,320
$176.25 P/Share
|
|
Sep 15
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Bona fide gift
|
Direct |
300
-0.25%
|
-
|
|
Sep 12
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,000
-8.48%
|
$855,000
$171.47 P/Share
|
|
Sep 02
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
3,000
-0.81%
|
$498,000
$166.6 P/Share
|
|
Sep 02
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
5,079
-1.05%
|
$843,114
$166.47 P/Share
|
|
Aug 28
2025
|
Rowan E Chapman |
SELL
Open market or private sale
|
Direct |
2,750
-31.37%
|
$456,500
$166.99 P/Share
|
|
Aug 14
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
678
-0.22%
|
$105,090
$155.38 P/Share
|
|
Aug 14
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
875
-0.35%
|
$135,625
$155.44 P/Share
|
|
Aug 12
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,675
+1.08%
|
-
|
|
Aug 12
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
1,675
+1.33%
|
-
|
|
Aug 11
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-0.85%
|
$459,000
$153.33 P/Share
|
|
Aug 08
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
3,070
-0.21%
|
$491,200
$160.97 P/Share
|
|
Aug 01
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
3,000
-0.8%
|
$399,000
$133.28 P/Share
|
|
Aug 01
2025
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
2,496
-16.46%
|
$331,968
$133.2 P/Share
|
|
Aug 01
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
5,807
-1.73%
|
$766,524
$132.87 P/Share
|
|
Jul 29
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,045
-1.5%
|
$417,165
$137.15 P/Share
|
|
Jul 28
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,019
-2.86%
|
$280,641
$139.81 P/Share
|
|
Jul 28
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
6,092
-3.47%
|
$846,788
$139.81 P/Share
|
|
Jul 28
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,994
-0.98%
|
$277,166
$139.81 P/Share
|
|
Jul 28
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
1,710
-1.11%
|
$237,690
$139.81 P/Share
|
|
Jul 28
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
2,206
-1.72%
|
$306,634
$139.81 P/Share
|
|
Jul 28
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
1,718
-0.07%
|
$238,802
$139.81 P/Share
|
|
Jul 28
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
479
-0.19%
|
$66,581
$139.81 P/Share
|
|
Jul 25
2025
|
Rowan E Chapman |
BUY
Grant, award, or other acquisition
|
Direct |
149
+1.67%
|
-
|
|
Jul 25
2025
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
108
+0.59%
|
-
|
|
Jul 25
2025
|
Monica Bertagnolli |
BUY
Grant, award, or other acquisition
|
Direct |
108
+2.06%
|
-
|
|
Jul 25
2025
|
Roelof Botha |
BUY
Grant, award, or other acquisition
|
Direct |
173
+2.52%
|
-
|
|
Jul 25
2025
|
Gail Boxer Marcus |
BUY
Grant, award, or other acquisition
|
Direct |
141
+1.68%
|
-
|
|
Jul 25
2025
|
Herm Rosenman |
BUY
Grant, award, or other acquisition
|
Direct |
153
+0.22%
|
-
|
|
Jul 25
2025
|
Brinkley Ruth Williams |
BUY
Grant, award, or other acquisition
|
Direct |
112
+2.1%
|
-
|
|
Jul 24
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
755
-0.53%
|
$104,945
$139.57 P/Share
|
|
Jul 23
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
495
-0.69%
|
$69,795
$141.28 P/Share
|
|
Jul 22
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.71%
|
-
|
|
Jul 22
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
920
-1.29%
|
$127,880
$139.58 P/Share
|
|
Jul 21
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
602
-0.84%
|
$83,678
$139.29 P/Share
|
|
Jul 21
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
1,622
-0.92%
|
$225,458
$139.29 P/Share
|